anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a gel-like composition that permits a large amount of a silicone oil to be stably incorporated into the composition and is good in usability.  <P>SOLUTION: The gel-like composition comprises an oil agent and a silicone elastic powder dispersed in a state of, or approaching that of a primary particle in the oil agent wherein the gel-like composition has a storage modulus at 25°C of 50-500 Pa with a ratio of loss modulus/storage modulus of 1.0 or less and on the other hand has a storage modulus at 80°C of 1-50 Pa with a ratio of loss modulus/storage modulus of 1.0 or more in the case when the stress is 1 Pa. Preferably, the oil agent in the composition is composed mainly of a non-volatile linear silicone oil. The silicone elastic powder is preferably contained in an amount of 1-50 mass% in the composition. Preferably, the composition further comprises a polyoxyalkylene-modified polysiloxane as a dispersant. A cosmetic material comprising the gel-like composition is provided.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Placebo drug will be administered once every 4 weeks by intrathecal bolus injection for a total of up to 4 doses. Treatment will be administered on Day 1, followed by repeat dosing every 4 weeks at approximately Day 29, Day 57 and Day 85.
Hypoplastic asymmetry due to hemifacial microsomia (HFM) often represents the most difficult reconstruction in the craniomaxillofacial clinic. Although autogenous grafts are generally used for temporomandibular joint reconstruction (TMJR), the use of TMJR prostheses is not well established. The aim of this review was to identify, collect and analyse the use of extended TMJR (eTMJR) prostheses in patients with HFM, describing clinical features, surgical procedures and postoperative complications. Online searches of all major databases were performed according to PRISMA guidelines. All studies with HFM patients treated with the eTMJR prostheses were included. Descriptive statistics were used for data analysis. A total of 19 studies, including 08 case studies, 06 case series and 05 retrospective cohort studies, met the inclusion criteria, where a total of 42 HFM patients were reported from 18 countries, mostly from the United States (05; 26%). Fifteen of the 42 cases (~36%) were male. The mean ± SD (range) age of patients in all studies was 19.79 ± 5.81 (9-36) years. The mean ± SD (range) of patient follow-up was 41.30 ± 35.50 (6-136) months. A total of 5 (10.6%) patients were implanted with bilateral eTMJR prostheses. The Pruzansky classification was used in 18 (~89.5%) studies, OMENS classification in 01 (~5%) study, whereas no classification was reported in one study. Only 01 (7.1%) study had documented the eTMJR classification for the prosthesis used. In growing patients with or without a history of failed autogenous tissues, TMJR prostheses may provide a viable alternative. Randomized studies with large cohorts are warranted to validate these preliminary results.
PURPOSE:To obtain a skin drug for external use, containing kojic acids and a specific plant extract ingredient having antiinflammatory action and having excellent skin anti-inflammatory and beautifying effects. CONSTITUTION:A skin drug for external use containing 0.0001-5wt.% kojic acid and/or a derivative thereof and an extract ingredient of one or two or more plants selected from Matricaria chamomilla L., Lithospermum officinale var. erythrorhizon, Goodyera procera Hooker, Salvia officinalis L., birch, Calendula officinalis L., Sambucus sieblodiana Blume, Typha latifolia L. and Hypericum erectum Thunb. in an amount of 0.0001-10wt.% expressed in terms of dry weight. Furthermore, an aqueous ingredient, surfactant, oil, humectant, alcohols, perfume, coloring matter, etc., are suitably blended therewith and prepared according to a conventional method to afford the objective substance. The aforementioned drug can be applied as a skin drug for external use of medicinal, quasi-drug or cosmetic applications such as milky lotion, cream, toilet water, pack, foundation, hair cosmetic or detergent and further the form of dispersion, ointment, granule, etc.
The present invention relates to a preparation technology and a production method for an integrated new formulation of a Hou's Black Powder, wherein the raw materials of active ingredients comprise: 40 parts by weight of chrysanthemum, 10 parts by weight of bighead atractylodes rhizome, 3 parts by weight of asarum herb, 3 parts by weight of poria cocos, 3 parts by weight of oyster, 8 parts by weight of balloonflower root, 10 parts by weight of divaricate saposhnikovia root, 3 parts by weight of ginseng, 3 parts by weight of aluminite, 5 parts by weight of radix scutellariae, 3 parts by weight of Chinese angelica, 3 parts by weight of dried ginger, 3 parts by weight of ligusticum wallichii, and 3 parts by weight of cinnamon twig. The production process of the integrated new formulation of Hou's Black Powder comprises the following steps of: supersonic air-jet crushing, alcohol-water extraction, ultrasonic crushing extraction, water decocting concentration, supersonic spray drying, nanometer grinding, high pressure homogenization, nano particle preparation and the like. According to the invention, the advantages, such as multi-synergism, multi-target, embodied by a nano-carrier coupling technique, are focused to be taken of. After the integrated new formulation of Hou's Black Powder is subjected to scale production, the production cost can be greatly reduced, the quality of products is greatly improved and the targeting property and the sustained and controlled release performance of the medicament are enhanced. The internal and external administration of the integrated new formulation of Hou's Black Powder can be realized simultaneously, and can be respectively taken in four time slices according to midnight-noon ebb-flow and qi and blood flowing rule of a human body. The integrated new formulation of Hou's Black Powder can be further prepared into films and transdermal agents which are respectively stuck to different parts of a human body according to the midnight-noon ebb-flow and qi and blood flowing rule of the human body and can be directly absorbed through skin.
PURPOSE:To provide a hair tonic having strong hair-tonic effect and sufficiently exhibiting the falling-off preventing effect, hair-growth promoting effect, etc. CONSTITUTION:This hair tonic contains at least one kind of compound selected from xanthine derivatives of the formula (R1 and R2 are H or 1-6C alkyl), e.g. theobromin, theophylline, 3-methyl-7-propylxanthine and 3-methyl-1- propylxanthine. The amount of the compound is 0.0001-10wt.% (preferably 0.001-5wt.%) based on the total hair-tonic. The hair tonic may be incorporated with other components such as minoxidil, diazoxide and various antiandrogenic agents to improve the hair-growing and hair-tonic effects. It can be used in pharmaceutical field, quasi-drug field and cosmetic field.
Rare cases of death or hospitalization due to severe liver injury have been reported post-marketing in association with the use of NILANDRON. Hepatotoxicity in these reports generally occurred within the first 3 to 4 months of treatment. Hepatitis or marked increases in liver enzymes leading to drug discontinuation occurred in 1% of NILANDRON patients in controlled clinical trials.  
Serum transaminase levels should be measured prior to starting treatment with NILANDRON, at regular intervals for the first 4 months of treatment, and periodically thereafter. Liver function tests should also be obtained at the first sign or symptom suggestive of liver dysfunction, e.g. nausea, vomiting, abdominal pain, fatigue, anorexia, "flu-like" symptoms, dark urine, jaundice or right upper quadrant tenderness. If at any time, a patient has jaundice or their ALT rises above 2 times the upper limit of normal, NILANDRON should be immediately discontinued with close followup of liver function tests until resolution.
Novel compounds of formula <FORM:1049840/C2/1> in which R1 is a phenyl or 5- or 6-membered heteroaromatic monocyclic radical that is unsubstituted or has from 1-3 substituents; R2 is a hydrogen atom, or a C1- 5 alkyl, aryl, or aralkyl radical which may be substituted by one or more alkoxy, halo, amino, substituted amino or nitro radicals, or is a C2- 5 alkenyl, cycloaliphatic or alkanyl radical; R3 is a halogenated methylene radical; R4 is hydroxy, amino, substituted amino, C1- 5 alkoxy, aralkoxy or -OM radical, M being a cation; R5 is a hydrogen or halogen atom, or a C1- 5 alkyl C1- 5 alkoxy, haloalkyl, nitro, amino, substituted amino, aryl, aryloxy, hydroxy, mercapto, sulphamoyl, sulphoxide, carboxy, carboalkoxy, cyano, aminomethyl, alkyl-substituted aminomethyl, dialkylsulphamoyl, or benzylmercapto radical; and R6 is a hydrogen atom or a C1- 5 alkyl or C2- 5 alkenyl radical; and the anhydride derivatives of the acids; are prepared by treating an indole of formula <FORM:1049840/C2/2> in which R1 is an alkyl or aralkyl group with a halogenated triphenyl phosphorane of formula (C6H5)3P = R13, and, if desired, hydrolysing the ester formed (R4 is alkoxy or aralkoxy) to the corresponding acid (R4 is hydroxy), which may be converted to a symmetrical or mixed anhydride which is reacted with ammonia, a primary or secondary amine, or an alkanol or aralkanol in the presence of a non-hydroxylic base to give the corresponding amide, substituted amide or ester of Formula (I) (R4 is amino, substituted amino, alkoxy or aralkoxy), or which may be esterified with an alkanol or aralkanol to produce the corresponding ester.  The 3-keto ester indole of Formula (II) may be prepared by reacting an oxalyl halide with the N-1 unsubstituted indole to give a 3-indole glyoxalyl halide which is then reacted with an alkanol or aralkanol to yield the alkyl or aralkyl 3-indoleglyoxalate the aralklyation or heteroaralkylation of which gives the N-1 aralkylated or hetero-aralkylated 3-keto ester indole of Formula (II).  The foregoing steps may be reversed, i.e. the indole may first be aralkylated in the N-1 position, followed by introduction of the 3-keto ester residue.  Therapeutic compositions having anti-inflammatory and antipyretic activity, which may be administered, e.g. orally, contain as active ingredients compounds of Formula (I) above.
Background: Personalized MR neuro-navigation-based targeting approaches have been developed that have the potential to greatly increase TMS efficacy. Nevertheless, these have yet to be incorporated into routine clinical practice because of issues related to 1) the feasibility of neuro-navigation when applied to routine clinical practice, and 2) lack of biomarker-based validation of the critical target across individuals. Recent research at CU has begun to address both feasibility and targeting issues. In the MR-guided neuro-navigation approach, either structural or functional brain scans are used to identify a specific region of interest and the neuro-navigation system is then used to position the TMS coil to target that specific region across individuals. While this approach can be applied within specialized treatment settings, use of these devices requires expertise in 3D brain reconstruction that the majority of TMS providers do not possess. At CU, an initiative is underway to develop a "virtual neuro-navigation" system in which MRI images of the head and brain are uploaded into a server and neuro-navigation is performed "in silico" rather than in person. Scalp coordinates are then relayed to the clinician.

Study: Under this phase I study, Soterix Medical would develop an initial version of the software ("TMSMap") and CU would perform feasibility testing on patients with treatment resistant depression
Process for preparing pharmacologically active compounds, useful for use in pharmaceutical compositions. The compounds produced by the process of this invention have a useful h2 histamine antagonist activity. These compounds can exist as acid addition salts. Histamine h2 antagonists can be defined as compounds that block histamine h2 receptors. H2 histamine receptors are not blocked by mepyramine and typical "antihistamines" (histamine h1 receptor antagonists), but are blocked by burimamide. Histamine h2 antagonists are useful as inhibitors of gastric acid secretion, as anti-inflammatory agents and as agents that act on the cardiovascular system. The products of the process of this invention are represented by the following formula i: ** (formula) **. (Machine-translation by Google Translate, not legally binding)
The invention relates to the field of biology, more specifically to the field of immunology and microbiology. The invention further relates to the field of vaccines against microbial infections and especially bacterial vaccines, in particular to pneumococcal vaccines. More in particular, the invention relates to means and methods to identify, select and isolate a vaccine component for passive and/or active immunisation against a microorganism that can be killed by opsonophagocytic cells. The invention relates to a method to identify an opsonophagocytosis inducing antigen as a vaccine component for immunisation against a microorganism. The invention describes three pneumococcal proteins SlrA, IgA1 proteinase, and PsaA, and their use as a vaccine component with or without PpmA. The invention also discloses the use of antibodies against said proteins for passive immunization and diagnosis.
Dantrium is metabolized by the liver, and it is theoretically possible that its metabolism may be enhanced by drugs known to induce hepatic microsomal enzymes. However, neither phenobarbital nor diazepam appears to affect Dantrium metabolism. Binding to plasma protein is not significantly altered by diazepam, diphenylhydantoin, or phenylbutazone. Binding to plasma proteins is reduced by warfarin and clofibrate and increased by tolbutamide.

Cardiovascular collapse in association with marked hyperkalemia has been reported in patients receiving dantrolene in combination with calcium channel blockers. It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis. 

Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.
The mechanisms of neuropathic pain (NP) are considered multifactorial. Alterations in the suppressor of cytokine signaling 1 (SOCS1) play a critical role in neural damage and inflammation. Epigenetic RNA modifications, specifically N6-methyladenosine (m6A) methylation, have increasingly been observed to impact the nervous system. Nevertheless, there is a scarcity of studies investigating the connection between m6A methylation and SOCS1 in the molecular mechanisms of NP. This study investigates the roles and potential mechanisms of the m6A methyltransferase like 3 (METTL3) and SOCS1 in female rats with spinal nerve ligation (SNL)-induced NP. It was found that in NP, both METTL3 and overall m6A levels were downregulated, leading to the activation of pro-inflammatory cytokines, such as interleukin-1β, interleukin 6, and tumor necrosis factor-α. Notably, The SOCS1 mRNA is significantly enriched with m6A methylation modifications, with the most prevalent m6A methyltransferase METTL3 stabilizing the downregulation of SOCS1 by targeting m6A methylation modifications at positions 151, 164, and 966.Exogenous supplementation of METTL3 improved NP-related neuroinflammation and behavioral dysfunctions, but these effects could be reversed by the absence of SOCS1. Additionally, the depletion of endogenous SOCS1 promoted NP progression by inducing the toll-like receptor 4 (TLR4) signaling pathway. The dysregulation of METTL3 and the resulting m6A modification of SOCS1 form a crucial epigenetic regulatory loop that promotes the progression of NP. Targeting the METTL3/SOCS1 axis might offer new insights into potential therapeutic strategies for NP.
PART B: 2 Participants from each of 4 cohorts (total of 8 participants) are to receive masking placebo tablet once daily for 14 days. There is to be dose escalation between cohorts. Participants are to be randomized within cohorts.
Omega-3 is a family of n-3 polyunsaturated fatty acids (PUFAs), which have been used to treat a wide variety of chronic diseases, due mainly to their antioxidant and anti-inflammatory properties, among others. In this context, omega-3 could be post-exercise recovery agent and sports supplement that could improve performance by preserving and promoting skeletal muscle mass and strength. No conclusive evidence, however, exists about the potential effects of omega-3 on post-exercise biomarkers and sports performance in physically healthy adults. Based on the PRISMA in Exercise, Rehabilitation, Sports Medicine, and Sports Science (PERSiST) guidelines, we systematically reviewed studies indexed in Web of Science, Scopus, and Medline to assess the effects of omega-3 on post-exercise inflammation, muscle damage, oxidant response, and sports performance in physically healthy adults. The search was performed on original articles published in the last 10 years up to 5 May 2024, with a controlled trial design in which omega-3 supplementation was compared with a control group. Among 14,971 records identified in the search, 13 studies met the selection criteria. The duration of the interventions ranged from 1 day to 26 weeks of supplementation and the doses used were heterogeneous. Creatine kinase (CK) and lactate dehydrogenase (LDH) were significantly higher (p < 0.05) in the control group in 3 of the 4 studies where these markers were analyzed. C-reactive protein (CRP) was significantly higher (p < 0.05) in the control group of 2 of the 13 studies where this marker was analyzed. The delayed onset muscle soreness (DOMS) gave mixed results. Interleukin 6 (IL-6) showed improvements with supplementation, but tumor necrosis factor-α (TNF-α) displayed no differences. The consumption of n-3 PUFAs improved some indicators of oxidative stress such as reduced glutathione (GSH)/oxidized glutathione (GSSG) ratio. Additional evidence is needed to establish clear recommendations regarding the dose and length of n-3 PUFA supplements. These may benefit the post-exercise inflammatory response, mitigate muscle damage, and decrease oxidative stress caused by exercise. However, studies did not evaluate omega-3 status at baseline or following supplementation and therefore the observations must be treated with caution.
Uses an electrical stimulator that opens the paretic hand and extends the paretic elbow in response to and with an intensity proportional to movement of the contralateral arm and hand. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 70 min of functional task practice twice a week in the laboratory for 12 weeks.
PROBLEM TO BE SOLVED: To obtain a cosmetic composition and a medicinal composition which has anti-inflammatory, antiallergic and antioxidant actions and is excellent in safety. SOLUTION: An extract of a plant (Selaginella moellendorfii Hieron) in Selaginella or one or more kinds of its fractionated products are used as active ingredients in an amount of 0.001-10wt.%. This active ingredient is properly formulated to conventional additives to prepare tooth paste, ointment, lotion, powder hair tonic, shampoo, rinse, treatment, mousse, juice, candy, tablets and the like. The extract is prepared by extracting raw or dried roots. leaves stems of the plant with an organic solvent such as ethanol. The extract is further partitioned with organic solvents and fractionated and isolated through chromatography and the like.
A method and apparatus for embedding an amount of cosmetic powder into a cosmetic pad, and a pre-powdered cosmetic pad thereof. The cosmetic pad generally includes a thin open-celled foam pad having a top face and a bottom face and an amount of cosmetic powder embedded into the top face of the pad so that the cosmetic powder is visible on the top face of the pad. In a method for embedding an amount of cosmetic powder into a cosmetic pad, a cosmetic pad is inserted into a chamber having an amount of cosmetic powder deposited therein and a pressure is applied within the chamber whereby an amount of cosmetic powder is drawn into the cosmetic pad and embedded therein. Preferably, a stencil having a decorative cut-out pattern is also inserted into the chamber between the cosmetic pad and the amount of cosmetic powder whereby, upon the application of pressure within the chamber, an amount of cosmetic powder is drawn through the stencil and embedded into the cosmetic pad. The apparatus generally includes a chamber having an inlet, an outlet and a cosmetic pad receiving space disposed between the inlet and the outlet. An amount of cosmetic powder is deposited within the chamber between the inlet and the cosmetic pad receiving space and a pressure source is connected to one or both of the inlet and the outlet for applying a pressure within the chamber to draw an amount of the cosmetic powder into a cosmetic pad inserted in the cosmetic pad receiving space. Preferably, a stencil having a decorative cut-out pattern is disposed between the cosmetic pad receiving space and the amount of cosmetic powder so that the cosmetic powder is drawn through the stencil into the pad in a decorative design.
Hormone-responsive breast cancer represents the most common type and has the best prognosis, but still approximately 40% of patients with this type can develop distant metastases, dramatically worsening the patient's survival. Monitoring metastatic breast cancer (mBC) for signs of progression is an important part of disease management. Circulating tumor cell (CTC) detection and molecular characteristics gain importance as a diagnostic tool, but do not represent a clinical standard and its value as a predictor of progression is not yet established. The main objective of this study was to estimate the prognostic value of not only the CTC numbers, but also the dynamics of the CTC numbers in the same patient during the continuous evaluation of CTCs in patients with advanced breast cancer. The other objective was to assess the molecular changes in CTCs compared to primary tumor samples by genetic analysis of the seven genes associated with estrogen signaling pathway, mutations in which are often responsible for the resistance to endocrine therapy, and subsequent progression. This approach was taken to evaluate if genetic analysis of CTCs can be used in tracking the resistance, signaling that hormonal therapy should be replaced. Consequently, this report presents the results of a longitudinal CTC study based on three subsequent blood collections from 135 patients with metastatic breast cancer, followed by molecular analysis of the isolated single CTCs. CTCs were detected and isolated using an image-based, EpCAM-independent system CytoTrack; this approach allowed evaluation of EpCAM expression in detected CTCs. Isolated CTCs were subjected to NGS analysis to assess mutational changes. The results confirm the importance of the status of the CTC for progression-free survival and overall survival and provide new data on the dynamics of the CTC during a long monitoring period and in relation to clinical progression, highlighting the advantage of constant monitoring over the single count of CTC. Furthermore, high genetic and phenotypic inter- and intrapatient heterogeneity observed in CTCs suggest that metastatic lesions are divergent. High genetic heterogeneity in the matching CTC/primary tumor samples may indicate early dissemination. The tendency towards the accumulation of activating/oncogenic mutation in CTCs, leading to anti-estrogen resistant disease, was not confirmed in this study.